Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold.

Hsp90 C-terminal ligands are potential new anti-cancer drugs alternative to the more studied N-terminal inhibitors. Here we report the identification of a new dihydropyrimidinone binding the C-terminus, which is not structurally related to other well-known natural and nature-inspired inhibitors of this second druggable Hsp90 site.

[1]  S. McAlpine,et al.  Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. , 2011, ACS chemical biology.

[2]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[3]  W. Pratt,et al.  Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1 , 2003, Experimental biology and medicine.

[4]  Qiuyun Liu,et al.  SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. , 2012, Cancer letters.

[5]  D. Mok,et al.  Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90 , 2006, Journal of Biological Chemistry.

[6]  Y. Miyata,et al.  The Therapeutic Target Hsp90 and Cancer Hallmarks , 2012 .

[7]  M. Theodoraki,et al.  Quality control and fate determination of Hsp90 client proteins. , 2012, Biochimica et biophysica acta.

[8]  Yang Wang,et al.  N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. , 2015, Chemical communications.

[9]  D. Taub,et al.  Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers , 2004, Cancer biology & therapy.

[10]  Yao Wang,et al.  Chemically accessible hsp90 inhibitor that does not induce a heat shock response. , 2014, ACS medicinal chemistry letters.

[11]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[12]  Giorgio Colombo,et al.  Exploiting Conformational Dynamics in Drug Discovery: Design of C-Terminal Inhibitors of Hsp90 with Improved Activities , 2014, J. Chem. Inf. Model..

[13]  C. Kappe.  Biologically active dihydropyrimidones of the Biginelli-type--a literature survey. , 2000, European journal of medicinal chemistry.

[14]  编辑部.  张礼和院士、周德敏教授应邀分别担Eur.J.Med.Chem.杂志和J.Med.Chem.杂志的编委 , 2014 .

[15]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[16]  Ta-Wei Lin,et al.  The Hexameric Structures of Human Heat Shock Protein 90 , 2011, PloS one.

[17]  G. Bifulco,et al.  Structural Insights for the Optimization of Dihydropyrimidin-2(1H)-one Based mPGES-1 Inhibitors. , 2015, ACS medicinal chemistry letters.

[18]  P. Csermely,et al.  A Nucleotide-dependent Molecular Switch Controls Atp Binding at the C-terminal Domain of Hsp90 N-terminal Nucleotide Binding Unmasks a C-terminal Binding Pocket* , 2022 .

[19]  P. Csermely,et al.  Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site. , 2003, European journal of biochemistry.

[20]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[21]  P. Csermely,et al.  Hsp90 isoforms: functions, expression and clinical importance , 2004, FEBS letters.

[22]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[23]  L. Pearl,et al.  Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex , 2006, Nature.

[24]  G. Giaccone,et al.  Update on Hsp90 inhibitors in clinical trial. , 2009, Current topics in medicinal chemistry.

[25]  R. Bhat,et al.  Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. , 2014, Journal of medicinal chemistry.

[26]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[27]  M. Cooper.  Label-free screening of bio-molecular interactions , 2003, Analytical and bioanalytical chemistry.

[28]  B. Blagg,et al.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. , 2008, Current medicinal chemistry.

[29]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[30]  M. Ferrarini,et al.  Unusual expression and localization of heat‐shock proteins in human tumor cells , 1992, International journal of cancer.

[31]  A. Leone,et al.  Identification of the Plant Compound Geraniin as a Novel Hsp90 Inhibitor , 2013, PloS one.

[32]  R. Condé,et al.  Modulation of Hsf1 activity by novobiocin and geldanamycin. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[33]  J. Kremsner,et al.  5-aroyl-3,4-dihydropyrimidin-2-one library generation via automated sequential and parallel microwave-assisted synthesis techniques. , 2007, Journal of combinatorial chemistry.

[34]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[35]  T. Gasiewicz,et al.  (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. , 2009, Biochemistry.

[36]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[37]  Wenjie Luo,et al.  Heat shock protein 90 in neurodegenerative diseases , 2010, Molecular Neurodegeneration.

[38]  G. Bifulco,et al.  A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors. , 2013, Journal of medicinal chemistry.

[39]  U Norinder,et al.  Experimental and computational screening models for the prediction of intestinal drug absorption. , 2001, Journal of medicinal chemistry.

[40]  M. Yazdanian,et al.  Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds , 1998, Pharmaceutical Research.

[41]  L. Whitesell,et al.  Altered Hsp90 function in cancer: a unique therapeutic opportunity. , 2004, Molecular cancer therapeutics.

[42]  G. Bifulco,et al.  Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E₂ synthase-1 enzyme (mPGES-1). , 2014, European journal of medicinal chemistry.